The new acromegaly drug ‘Somavert’ may now be prescribed at general hospitals in Korea.

According to industry sources, Pfizer Korea’s Somavert (pegvisomant) has passed the review of Drug Committees at the ‘Big 5’ tertiary hospitals in Korea including the Samsung Medical Center, Seoul National University Hospital, Seoul St.Mary’s Hospital, Asan Medical Center and Shinchon Severance Hospital.

The drug can now be prescribed at most major hospitals in Korea. As Somavert has been listed for insurance benefit in September last year, no barriers remain in patients' access to the drug.

Acromegaly, which is also known as giantism, is a rare condition characterized by the exc